What Will Happen to Aptevo Therapeutics Inc. (APVO) Next? The Stock Formed a Several Months Bullish Wedge Up

December 7, 2017 - By Marry Poplack

The stock of Aptevo Therapeutics Inc. (APVO) formed an up wedge with $4.00 target or 6.00 % above today’s $3.77 share price. The 6 months wedge indicates low risk for the $80.79 million company. If the $4.00 price target is reached, the company will be worth $4.85M more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 0.53% or $0.02 during the last trading session, reaching $3.77. About 330,949 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has 0.00% since December 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Analysts await Aptevo Therapeutics Inc. (NASDAQ:APVO) to report earnings on March, 30. They expect $-0.66 earnings per share, down 6,700.00 % or $0.67 from last year’s $0.01 per share. After $0.14 actual earnings per share reported by Aptevo Therapeutics Inc. for the previous quarter, Wall Street now forecasts -571.43 % negative EPS growth.

More notable recent Aptevo Therapeutics Inc. (NASDAQ:APVO) news were published by: Seekingalpha.com which released: “Aptevo Therapeutics Likely Worth At Least $5 A Share” on September 01, 2017, also Globenewswire.com with their article: “Aptevo Therapeutics Reports Second Quarter 2017 Financial Results” published on August 10, 2017, Globenewswire.com published: “Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update” on March 31, 2017. More interesting news about Aptevo Therapeutics Inc. (NASDAQ:APVO) were released by: Seekingalpha.com and their article: “Aptevo Therapeutics: Slowly Grinding Higher” published on October 12, 2017 as well as Globenewswire.com‘s news article titled: “Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab …” with publication date: November 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.